The emerging view on the roles of butyrate in Clostridioides difficile pathogenesis
Infection and Immunity · 14.10.2025 · 93 (10)
DOI: 10.1128/iai.00047-25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Infection and Immunity, erschienen am 14.10.2025. Verfasst von Horia A Dobrila und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, W…. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections, Butyrates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation, Judy L. and Sal A. Troia Professorship in Gastrointestinal Disease Research.
Abstract (Originalsprache)
The Centers for Disease Control and Prevention classifies Clostridioides difficile as an urgent threat to the nation’s health, as it causes 450,000 infections, 15,000 deaths, and 1 billion dollars in excess healthcare costs per year in the United States. Current treatments for C. difficile infections (CDIs) are antibiotics and, in recurrent cases, microbiome restoration therapy (MRT). Antibiotics contribute to antibiotic resistance and recurrent CDIs. Although MRTs (e.g., defined consortia of microbes or fecal transplant) are increasingly accessible, the long-term sustainability and accessibility of these treatments remain to be determined. These limitations highlight the need for more precise strategies for coping with CDI. Because a disrupted (dysbiotic) gut microbiome is the primary risk factor for CDI, a better understanding of the interactions between C. difficile , the microbiome, and the host will aid the development of such treatments. Butyrate is a prominent microbiome-host co-metabolite that is influenced by host dietary fiber intake and differentiates healthy from dysbiotic gut ecosystems. Emerging evidence supports that butyrate is a key determinant of C. difficile fitness and pathogenesis. Here, we review the current literature and gaps in knowledge about how butyrate-rich gut environments exclude C. difficile , and how butyrate impacts C. difficile growth, metabolism, toxin production/release, and sporulation. We further discuss the implications of continued study of butyrate’s impacts on CDI, including the eventual development of new strategies to mitigate CDI in at-risk human populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Gastroenterology and Hepatology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
- Microbiology Doctoral Training Program, University of Wisconsin-Madison, Madison, Wisconsin, USA.
ORCID-Profile: Horia A Dobrila, Andrew J Hryckowian
Förderung
- National Science Foundation
- Judy L. and Sal A. Troia Professorship in Gastrointestinal Disease Research
Zitieren
APA
Dobrila, H. A., & Hryckowian, A. J. (2025). The emerging view on the roles of butyrate in Clostridioides difficile pathogenesis. Infection and Immunity, 93(10). https://doi.org/10.1128/iai.00047-25
Vancouver
Dobrila HA, Hryckowian AJ. The emerging view on the roles of butyrate in Clostridioides difficile pathogenesis. Infection and Immunity. 2025;93(10). doi:10.1128/iai.00047-25
BibTeX
@article{Dobrila2025,
author = {Dobrila, Horia A and Hryckowian, Andrew J},
title = {The emerging view on the roles of butyrate in Clostridioides difficile pathogenesis},
journal = {Infection and Immunity},
year = {2025},
volume = {93},
number = {10},
doi = {10.1128/iai.00047-25}
}
EUVIMED